Lipocine (NASDAQ:LPCN) Now Covered by Analysts at StockNews.com

StockNews.com started coverage on shares of Lipocine (NASDAQ:LPCN) in a report released on Wednesday morning. The brokerage issued a hold rating on the specialty pharmaceutical company’s stock.

Lipocine Price Performance

NASDAQ LPCN opened at $3.19 on Wednesday. Lipocine has a 12 month low of $2.96 and a 12 month high of $11.79. The company has a 50-day moving average of $4.36 and a 200-day moving average of $4.58. The company has a market cap of $17.03 million, a P/E ratio of -4.19 and a beta of 1.23.

Institutional Inflows and Outflows

A hedge fund recently raised its stake in Lipocine stock. Geode Capital Management LLC lifted its position in shares of Lipocine Inc. (NASDAQ:LPCN) by 6.0% in the fourth quarter, according to its most recent 13F filing with the SEC. The firm owned 57,464 shares of the specialty pharmaceutical company’s stock after purchasing an additional 3,248 shares during the quarter. Geode Capital Management LLC owned about 1.07% of Lipocine worth $280,000 as of its most recent filing with the SEC. 9.11% of the stock is currently owned by institutional investors.

About Lipocine

Lipocine Inc, a clinical-stage biopharmaceutical company, engages in the research and development for the delivery of drugs for the treatment of central nervous system (CNS) disorders. Its lead product candidate is TLANDO, an oral testosterone replacement therapy (TRT) comprising testosterone undecanoate.